step 2 — how it works
Tesamorelin Mechanism of Action: GHRH Receptor, GH and IGF-1
Five sequential steps, walked down the board: receptor binding, the cAMP spark, pulsatile growth-hormone release, hepatic IGF-1, and visceral-fat lipolysis.
The short version
The tesamorelin mechanism of action is a five-step cascade you can read top to bottom. Tesamorelin docks onto the GHRH receptor (a switch on the pituitary gland) and flips it on. That fires a chemical spark called cAMP inside the cell, which makes the pituitary release the body's own growth hormone in natural bursts. The growth hormone then tells the liver to pump out IGF-1 (a growth signal), and together they coax fat cells — mostly the deep belly kind — to release their stored fat. In short: tesamorelin doesn't supply growth hormone, it presses the body's own "make growth hormone" button.
Step 1 — Tesamorelin binds the GHRH receptor
The cascade starts at the GHRH receptor (GHRH-R), a Gs-coupled G-protein-coupled receptor sitting on anterior-pituitary somatotrophs — the specialized pituitary cells that make growth hormone [4]. Tesamorelin is shaped to fit this receptor because it is a stabilized analogue of the natural ligand, GHRH(1-44) [6]. The crucial design detail is the trans-3-hexenoic acid group on its N-terminus: it blocks DPP-IV, the enzyme that normally cleaves and inactivates native GHRH within minutes, so tesamorelin stays intact long enough to bind and signal [6].
Step 2 — The cAMP spark and GH gene transcription
Once tesamorelin occupies the receptor, the Gs protein switches on adenylyl cyclase, which raises intracellular cAMP — think of cAMP as the cell's "go" messenger [4]. Rising cAMP activates PKA, which phosphorylates the transcription factor CREB; that turns up growth-hormone gene transcription and primes the secretory granules for release. This is the molecular spark that converts a binding event at the cell surface into more growth hormone being manufactured and readied inside the somatotroph [4].
Step 3 — Pulsatile growth hormone release
The result is a release of the body's own growth hormone in its natural pulsing rhythm, rather than the flat, continuous level you would get from injecting recombinant growth hormone [7]. In 13 healthy men, tesamorelin 2 mg/day for two weeks raised mean overnight growth hormone by +0.5 ug/L (P=0.004) [4]. That preserved pulsatility is part of why the metabolic profile of a GHRH analogue differs from supplying exogenous hormone, and why reviews describe GRF analogues as potentially better tolerated than recombinant growth hormone [7].
Step 4 — Hepatic IGF-1 synthesis
Growth hormone travels to the liver and, through JAK2/STAT5 signaling, drives synthesis and secretion of IGF-1 (insulin-like growth factor-1), the growth signal that carries out many of growth hormone's downstream effects [4]. The IGF-1 response is the most consistently measured biomarker in the tesamorelin literature: it rose 81.0% over 26 weeks in the pivotal HIV trial [1] and by 181 ug/L (P<0.0001) in healthy men [4]. An earlier 12-week dose-ranging study showed the response is dose-related — IGF-I rose +48% at 1 mg and +65% at 2 mg versus placebo [8].
Step 5 — Visceral-fat lipolysis
Finally, growth hormone and IGF-1 together activate hormone-sensitive lipase, the enzyme that breaks stored triglycerides into free fatty acids — lipolysis [1]. The effect concentrates in visceral adipose tissue (the metabolically active fat around the abdominal organs) rather than subcutaneous fat. A 2021 analysis added a quality dimension: over 26 weeks tesamorelin raised visceral-fat CT density by +6.2 HU and subcutaneous-fat density by +4.0 HU versus placebo (both P<0.0001), suggesting improved fat-tissue quality independent of how much fat was lost [11].
Half-life and why once-daily dosing works
Tesamorelin clears the plasma fast, yet its effect lasts the day — and that gap is the answer to the common tesamorelin half life question. Population pharmacokinetic modeling reported apparent plasma clearance of approximately 1,060 L/h with no clinically relevant demographic covariates, and roughly a 13% increase in absorbed fraction by day 14 versus day 1 [16]. Secondary sources, including the FDA label, describe a terminal half-life on the order of 26-38 minutes [14]. The reconciliation: even though the peptide itself is gone within the hour, the IGF-1 it triggers stays elevated across the dosing interval — which is exactly why a once-daily 2 mg subcutaneous regimen is the studied paradigm [16][14]. We summarize the studied dosing regimens separately.